| 证券代码：300452 | 证券简称：山河药辅 | 公告编号：2023-053 | | --- | --- | --- | | 债券代码：123199 | 债券简称：山河转债 | | 安徽山河药用辅料股份有限公司 第五届董事会第十六次会议决议公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏。 具体内容详见公司同日披露在巨潮资讯网（www.cninfo.com.cn）的 《关于不向下修正"山河转债"转股价格的公告》。 公司董事长尹正龙先生、董事宋道才先生、刘自虎先生、雷韩芳女 士持有公司本次发行的可转换公司债券，在审议本议案时回避表决。 表决结果：同意 5 票，反对 0 票，弃权 0 票。回避 4 票。 本议案获得通过。 备查文件: 安徽山河药用辅料股份有限公司（以下简称"公司"）第五届董事会 第十六次会议于于 2023 年 8 月 9 日下午 15：30 在公司三楼会议室召 开，应出席会议董事 9 人，实际出席会议董事 9 人。根据《公司章程》 第一百一十六条规定，"情况紧急，需要尽快召开董事会临时会议的，可 以随时通过电话或者其他口头方式发出会议通知，但召集人应当在 ...

投资者关系活动记录表 证券代码：300452 证券简称：山河药辅 安徽山河药用辅料股份有限公司投资者关系活动记录表 编号：2023-003 | | □特定对象调研 | □分析师会议 | | --- | --- | --- | | | □媒体采访 | □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 | 路演活动  | | | □现场参观 | | | | □其他 | | | 参与单位名称及人员姓名 | 参与山河药辅可转债发行网上路演的投资者 | | | 时间 | 2023 年 6 月 9 日 15：00-17：00 | | | 接待人员姓名 | 董事长、总经理：尹正龙 | | | | 财务总监、董事会秘书：刘琦 | | | | 国元证券 党委副书记、执委会副主任、副总裁：胡伟 | | | | 国元证券 保荐代表人：朱焱武 | | | | 国元证券 保荐代表人：杨凯强 | | | 地点 | "全景•路演天下"（http://rs.p5w.net） | | 第 1 页 共 17 页 投资者关系活动记录表 投资者提出的问题及公司回复情况 问题 1、"请问本次发行的可转债向公司股东配售的安排 是？ 回答：您 ...

安徽山河药用辅料股份有限公司投资者关系活动记录表 编号：2023-002 证券代码：300452 证券简称：山河药辅 投资者关系活动记录表 | | □特定对象调研 □分析师会议 | | --- | --- | | | □媒体采访 □业绩说明会 | | 投资者关系活动类别 | □新闻发布会 □路演活动 | | | □现场参观 | | | √其他（电话交流会） | | | 【中信证券】：陈竹、甘坛焕、唐寅灏、陈志；【西南证券】： | | | 杜向阳、杨天笑；【光大证券】：林小伟、曹聪聪；【国都 | | | 证券】：文惠霞；【方正证券】：唐爱金、宋丹；【首创证 | | | 券】王斌、李雯；【山西证券】贾赛东；【东方证券】韩冰； | | | 【淡水泉投资】：吴竞尧；【创金合信基金】：皮劲松；【华 | | | 宝基金】：陶庆波；【域秀资产】：刘云鹏；【理成资产】 | | | 周锐；【庶达资产】：李淑花；【银河基金】：方伟；【招 | | | 商证券】：邱捷铭；【广发基金】：王岩；【华安基金】： | | | 王斌；【华夏基金】：胥梦缘；【禾其投资】：潘峰；【华 | | | 能贵诚信托】：孙宇；【大成基金】：陈泉龙、杨挺；【 ...

Financial Performance - The company's revenue for Q1 2023 was CNY 247.71 million, representing a year-on-year increase of 29.42% compared to CNY 191.40 million in the same period last year[4]. - Net profit attributable to shareholders was CNY 49.39 million, up 45.95% from CNY 33.84 million in the previous year[4]. - The net profit after deducting non-recurring gains and losses was CNY 45.69 million, reflecting a 52.60% increase from CNY 29.94 million year-on-year[4]. - Total operating revenue for Q1 2023 reached ¥247,713,230.60, an increase of 29.5% compared to ¥191,403,805.41 in the same period last year[24]. - Net profit for Q1 2023 was ¥50,996,500.65, representing a 52.2% increase from ¥33,506,761.62 in Q1 2022[25]. - The total comprehensive income for the first quarter of 2023 was CNY 50,996,500.65, compared to CNY 33,506,761.62 in the same period last year, representing an increase of approximately 52%[26]. - The net profit attributable to the parent company was CNY 49,388,285.35, up from CNY 33,838,831.74, indicating a growth of about 46% year-over-year[26]. - Basic and diluted earnings per share increased to CNY 0.21 from CNY 0.14, reflecting a rise of approximately 50%[26]. Cash Flow and Liquidity - The company's cash flow from operating activities was negative CNY 1.26 million, a decrease of 125.79% compared to a positive CNY 4.88 million in the same period last year[4]. - Cash inflows from operating activities totaled CNY 184,202,846.77, compared to CNY 143,339,114.30 in the previous year, marking an increase of about 28.5%[28]. - The net cash flow from operating activities was negative at CNY -1,258,762.15, a decline from CNY 4,881,325.98 in the same quarter last year[28]. - Cash inflows from investment activities were CNY 155,721,467.41, up from CNY 123,167,091.29, showing an increase of approximately 26.4%[29]. - The net cash flow from investment activities was CNY -9,997,024.09, compared to CNY 8,716,707.74 in the previous year, indicating a significant decrease[29]. - Cash inflows from financing activities were CNY 5,000,000.00, down from CNY 9,000,000.00, reflecting a decrease of about 44.4%[29]. - The ending balance of cash and cash equivalents was CNY 110,987,658.02, down from CNY 137,510,031.01, a decrease of approximately 19.3%[29]. - The company's cash and cash equivalents decreased by CNY 11.72 million, a decline of 187.09% compared to the previous year, primarily due to reduced cash flow from operating and investing activities[11]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 1.21 billion, an increase of 2.22% from CNY 1.18 billion at the end of the previous year[4]. - The total assets at the end of Q1 2023 amounted to ¥1,206,722,590.22, compared to ¥1,180,550,962.11 at the beginning of the year, reflecting a growth of 2.0%[22]. - The total liabilities decreased to ¥366,591,138.42 from ¥391,933,246.05, a reduction of 6.5%[22]. - The company's equity attributable to shareholders rose to ¥772,401,548.03 from ¥722,521,885.86, an increase of 6.9%[22]. Research and Development - The company reported a significant increase in R&D expenses, totaling CNY 12.59 million, which is a 40.52% increase year-on-year[9]. - Research and development expenses increased to ¥12,592,178.62, a rise of 40.5% compared to ¥8,961,385.05 in the previous year[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,125[13]. - The largest shareholder, Yin Zhenglong, holds 26.89% of the shares, totaling 63,057,454 shares[13]. - Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. holds 11.20% of the shares, amounting to 26,254,059 shares[14]. - Liu Tao, an individual shareholder, owns 1.78% of the shares, which is 4,181,233 shares[14]. - The total number of restricted shares held by Yin Zhenglong is 47,293,090, which are subject to lock-up due to executive incentives[17]. - The company has no plans to lift restrictions on any shares during the reporting period[15]. - The report indicates that there are no related party transactions among the top shareholders[15]. - There are no significant changes in the number of preferred shareholders or their holdings[16]. Product Development and Market Strategy - The company has introduced new products including cellulose acetate and colloidal silica, and has been recognized as a "national green factory"[7]. - The company has not disclosed any new product developments or market expansion strategies in this report[19]. - The company has not reported any mergers or acquisitions during this period[19]. Audit and Reporting - The first quarter report was not audited, indicating that the figures are preliminary and subject to change[30].

Financial Performance - The company's operating revenue for 2022 was CNY 704,525,235.45, representing a 14.24% increase compared to CNY 616,707,253.38 in 2021[18]. - The net profit attributable to shareholders for 2022 was CNY 130,708,710.84, a significant increase of 46.45% from CNY 89,253,357.77 in the previous year[18]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 119,663,169.13, up 50.79% from CNY 79,358,791.40 in 2021[18]. - The basic earnings per share for 2022 was CNY 0.56, reflecting a 47.37% increase from CNY 0.38 in 2021[18]. - The total assets at the end of 2022 amounted to CNY 1,180,550,962.11, a 22.64% increase from CNY 962,583,989.34 at the end of 2021[18]. - The net assets attributable to shareholders at the end of 2022 were CNY 722,521,885.86, which is a 12.89% increase from CNY 640,000,201.75 in 2021[18]. - The cash flow from operating activities for 2022 was CNY 132,817,316.90, an increase of 27.93% compared to CNY 103,823,162.32 in 2021[18]. - The weighted average return on equity for 2022 was 19.39%, up from 14.76% in 2021, indicating improved profitability[18]. Industry Overview - The total revenue for the pharmaceutical manufacturing industry in China was CNY 29,111.4 billion in 2022, a decrease of 1.6% year-on-year[29]. - The total profit for the pharmaceutical manufacturing industry in China was CNY 4,288.7 billion in 2022, down 31.8% compared to the previous year[29]. - The average price reduction for selected drugs in the sixth batch of national centralized procurement reached 48%, with some products seeing reductions of over 70%[30]. - The market for pharmaceutical excipients in China is projected to reach CNY 140.6 billion by 2025, indicating significant growth potential[32]. - The global pharmaceutical excipients market is expected to reach USD 85.3 billion in 2023, highlighting the industry's expansive opportunities[32]. Product Development and Innovation - The company is focusing on technological innovation and aligning with international standards to enhance the quality of pharmaceutical excipients[31]. - The company has developed 39 products that have obtained registration numbers from the CDE, and several products have received the Food Production License from the Anhui Provincial Market Supervision Administration[34]. - Key products include microcrystalline cellulose, hydroxypropyl methylcellulose, and sodium carboxymethyl starch, which are recognized as high-tech products in Anhui Province[33]. - The company has achieved multiple certifications, including 10 EXCiPACT certifications and 14 DMF registrations in the US, enhancing its product quality and market competitiveness[44]. - The company successfully developed injection-grade excipients, marking a breakthrough in the injection-grade excipient field[51]. Market Strategy and Expansion - The company has established a marketing network with over 2,700 pharmaceutical manufacturers across more than 30 provinces and regions in China[48]. - The company’s export business has maintained high growth, with products exported to countries including Germany, the UK, and the USA[48]. - The company aims to maintain its position as a specialized and diversified manufacturer in the pharmaceutical excipient industry[34]. - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share within the next two years[125]. - A strategic acquisition of a local competitor is being considered to enhance production capabilities and market reach[125]. Financial Management and Governance - The company has established a fair and effective performance evaluation and incentive mechanism for senior management, combining basic annual salary with year-end performance assessments[106]. - The board of directors consists of 9 members, including 3 independent directors, meeting legal and regulatory requirements[104]. - The company has a complete and independent financial accounting system, with no instances of using company assets or credit for guarantees related to the controlling shareholder[111]. - The company has implemented a comprehensive internal control system to enhance governance and ensure the achievement of operational goals[107]. - The company has established a robust quality control system to ensure the production of high-quality pharmaceutical auxiliary materials[176]. Environmental and Social Responsibility - The company actively engages in environmental protection, ensuring that all pollutants are discharged in compliance with national standards, with no major environmental pollution incidents reported[177]. - The company has committed to energy-saving measures, setting annual targets for energy reduction and continuously promoting technological upgrades[177]. - The company emphasizes corporate social responsibility, participating in various public welfare activities and supporting vulnerable groups such as impoverished students[179]. - In 2022, the company donated 200,000 yuan to the Huainan Charity Association for epidemic prevention and provided 30,000 yuan worth of epidemic prevention materials to the Economic Development Zone[179]. - The company has established an emergency response plan for environmental incidents, which has been filed with the relevant environmental protection bureau[171]. Risk Management - The company has identified risks related to raw material price fluctuations and increased foreign trade costs, which may impact future performance[5]. - The company faces risks from raw material price fluctuations, which could impact production costs and profit margins[92]. - The company is expanding its international market presence, but rising foreign trade costs and currency fluctuations pose risks to profit margins[93]. - The company has established a risk management organization comprising the audit committee and internal audit department to oversee internal control management[155]. Employee Management and Compensation - The company reported a total of 905 employees at the end of the reporting period, with 580 in production, 80 in sales, 175 in technical roles, 14 in finance, and 56 in administration[140]. - The company’s remuneration policy aligns with job value and differentiates based on technical and professional capabilities, establishing a salary grading system[141]. - The total pre-tax remuneration for directors, supervisors, and senior management amounted to CNY 348.11 million[131]. - The highest remuneration was received by the Chairman and General Manager, totaling CNY 82.38 million[131]. - The company has established annual training plans based on departmental needs and past feedback, which are approved and executed by the human resources department[142].

证券代码：300452 证券简称：山河药辅 公告编号：2023-014 安徽山河药用辅料股份有限公司 出席本次业绩说明会的人员有：公司董事长兼总经理尹正龙先 生，独立董事林平先生，董事、副总经理雷韩芳女士，财务负责人、 董事会秘书刘琦先生。 为充分尊重投资者、提升交流的针对性，现就公司 2022 年度业 绩说明会提前向投资者公开征集问题，广泛听取投资者的意见和建 议。投资者可于 2023 年 4 月 14 日（星期五）12:00 前访问 http://ir.p5w.net/zj/，或扫描下方二维码，进入问题征集专题页 面。公司将在 2022 年度业绩说明会上，对投资者普遍关注的问题进 行回答。 （问题征集专题页面二维码） 关于举行 2022 年度业绩说明会暨问题征集的公告 本公司及董事会全体成员保证本公告内容不存在任何虚假记 载、误导性陈述或者重大遗漏。 安徽山河药用辅料股份有限公司定于 2023 年 4 月 14 日（星 期五）15:00－17:00 在全景网举办 2022 年度业绩说明会，本次年 度业绩说明会将采用网络远程的方式举行，投资者可登陆全景网"投 资者关系互动平台"（http://ir.p5w. ...

1.公司未来的战略规划？ 答：内生增长和外延扩张，短期还是聚焦药用辅料。很多企业做的是单品种，公 司目前有 21 个品种，未来会继续推出前景较好品种，但会在能力范围之内有 所控制。短期还是口服固体制剂领域做发展，产品线扩张上还是沿着这条线走 （固体制剂占全部药物制剂 70%）。国内在用的药用辅料 500 多种，西方发达 国家已达 1000 多种，公司的定位主要在比较新型药用辅料，传统的有淀粉、蔗 糖、糊精。 2.外延目标的选择？ 答：公司目前产品主要集中在口服固体制剂药用辅料，在注射剂或其他剂型相 对较少，且高端市场为国外厂商占比较大。公司产品目前有 21 个品种，40 多 个规格。如果有互补品种或个别优势品种的标的，公司也会考虑。 3.公司的突出竞争优势？ 答：公司始终坚持技术服务带动销售的营销模式（技术营销模式），提供给客 户辅料运用知识与技巧等技术支持，并根据各个企业不同功能性指标的要求定 制化的生产客户所需要的产品，提供差异化的服务,替代进口产品。目前行业集 中度相对较低，多数药用辅料生产企业仍以关系营销为主要营销途径，公司的 技术营销在行业内较为突出，专业化带来较高的客户粘性，未来有望进一步扩 大优 ...

安徽山河药用辅料股份有限公司 特定对象来企调研会议纪要 时间：2015 年 11 月 3 日 地点：公司三楼多功能会议室 参加人员：山河药辅董事长兼总经理 尹正龙 山河药辅董事会秘书 胡浩 瑞锐投资管理质询（上海）有限公司 陆慧 长城证券股份有限公司 赵浩然 农银汇理基金管理有限公司 陈卫国 华夏基金 刘志军 浙江浙商证券资产管理有限公司 赵媛 中欧基金管理有限公司 葛兰 上投摩根 罗会礼 中海基金管理有限公司 郑辰 信诚基金 杨强 交银康联人寿 徐志华 长江证券 张进 兴业证券 孙媛媛 交银施罗德 楼慧源 金鹰基金 赵志永 会议内容: 1.公司未来的战略规划？ 答：内生增长和外延扩张，短期还是聚焦药用辅料。很多企业做的是单品种，公 司目前有 21 个品种，未来会继续推出前景较好品种，但会在能力范围之内有 所控制。短期还是口服固体制剂领域做发展，产品线扩张上还是沿着这条线走 （固体制剂占全部药物制剂 70%）。国内在用的药用辅料 500 多种，西方发达 国家已达 1000 多种，公司的定位主要在比较新型药用辅料，传统的有淀粉、蔗 糖、糊精。 2.外延目标的选择？ 答：公司目前产品主要集中在口服固体制剂药用辅料 ...

(本页无正文,为调研人员对以上调研内容的确认签署页) | --- | --- | --- | --- | |-------|------------|-----------------------------|-------| | 序 号 | 姓名 | 所属单位 | 备注 | | 1 | 陆线. | 始就投资管理咨询 山海服务。 | | | 2 | 放在此 | ******** ? . | | | 3 | Path 2 12) | 版视汇 72 72 75 2 | | | 4 | 21 左な | 年度美容 | | | 5 | 越 | 洲商负管. | | | 6 | 高 | 中欧某会 | | | 7 | 男会社 | 上方法所在。 | | | 8 | 郑 后 | 中海萬宝 | | | 9 | 180 382 | 偿诚易金 | | | 10 | 练志. 年 | 之姐居院人寿. | | | 11 | 张 Ma | KiL HE K | | | 12 | 孙媛媛 | 兴业证券 | | | 13 | 1333原 | 反贸易贸易 | | ...